Patient Satisfaction with CIMZIA(®) (Certolizumab Pegol) AutoClicks(®) in the UK

por Bailey, Kathryn, Mountian, Irina, Bruggraber, Richard, Sunderland, Kerri, Tilt, Nicola, Szegvari, Boglarka
Publicado 2020

Long-Term Durability of Certolizumab Pegol in Patients with Rheumatoid Arthritis Over 5 Years: An Analysis of Pooled Clinical Trial Data

por Bykerk, Vivian P., Nash, Peter, Nicholls, David, Tanaka, Yoshiya, Winthrop, Kevin, Popova, Christina, Tilt, Nicola, Haaland, Derek
Publicado 2023

Efficacy and Safety of Certolizumab Pegol in Japanese Patients with Moderate to Severe Plaque Psoriasis: 52-Week Results

por Umezawa, Yoshinori, Asahina, Akihiko, Imafuku, Shinichi, Tada, Yayoi, Sano, Shigetoshi, Morita, Akimichi, Sakurai, Shinya, Hoshii, Naoki, Tilt, Nicola, Nakagawa, Hidemi
Publicado 2021

Associations Between Safety of Certolizumab Pegol, Disease Activity, and Patient Characteristics, Including Corticosteroid Use and Body Mass Index

por Bykerk, Vivian P., Blauvelt, Andrew, Curtis, Jeffrey R., Gaujoux‐Viala, Cécile, Kvien, Tore K., Winthrop, Kevin, Tilt, Nicola, Popova, Christina, Mariette, Xavier, Haraoui, Boulos
Publicado 2021

Publisher Correction: Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Stu...

por Gisondi, Paolo, Gottlieb, Alice B., Elewski, Boni, Augustin, Matthias, McBride, Sandy, Tsai, Tsen-Fang, de la Loge, Christine, Fierens, Frederik, López Pinto, José M., Tilt, Nicola, Lebwohl, Mark
Publicado 2023

Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CI...

por Gisondi, Paolo, Gottlieb, Alice B., Elewski, Boni, Augustin, Matthias, McBride, Sandy, Tsai, Tsen-Fang, de la Loge, Christine, Fierens, Frederik, López Pinto, José M., Tilt, Nicola, Lebwohl, Mark
Publicado 2022